Sarepta Therapeutics Announces Third Quarter 2017 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Sarepta Therapeutics (SRPT) Tops Q3 EPS by 7c; Raises FY Revenue outlook
October 25, 2017 4:08 PM EDTSarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($0.78), $0.07 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $46 million versus the consensus estimate of $40.77 million.
GUIDANCE:
Sarepta Therapeutics sees FY2017 revenue of $150-155 million, versus the consensus of... More
